Dr. Chunfeng Li 李春峰
Chief Physician, Associate Professor
Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of gastrointestinal diseases and tumors.
Dr. Li holds a medical doctorate and completed postdoctoral research in traditional Chinese medicine at Harbin Medical University. As a Chief Physician and Associate Professor, Dr. Li specializes in surgical oncology for gastrointestinal tumors.
Professional roles
- Standing Committee Member, Traditional Medicine Specialty Evaluation Professional Committee, China Association of Ethnic Medicine
- Member, Gastric Cancer Professional Committee, China Anti-Cancer Association
- Member, Gastric Tumor Branch, Heilongjiang Medical Association
- Reviewer, Journal of Practical Oncology
Name order: in Chinese the family name comes first (Li Chunfeng). Papers usually list the name as Chunfeng Li or Li C.
Selected publications
36 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- FASEB J, 2026 (senior author): Explainable Deep Learning of Transcriptomes Prioritizes Candidate Biomarkers With Preferential Performance in Gastric Cardia Cancer Cohorts. PubMed 42667125
- In Vitro Cell Dev Biol Anim, 2024 (senior author): Eco-friendly green synthesis of N‑pyrazole amino chitosan using PEG-400 as an anticancer agent against gastric cancer cells via inhibiting EGFR. PubMed 38564118
- Comput Math Methods Med, 2021 (senior author): Short-Term Efficacy and Quality of Life of Gastric Cancer Patients Undergoing Radical Gastrectomy Assisted by External Vision. PubMed 34899964
- Bioengineered, 2021 (first author): Angelica sinensis polysaccharide (ASP) attenuates diosbulbin-B (DB)-induced hepatotoxicity through activating the MEK/ERK pathway. PubMed 34229534
- Cell Biosci, 2021 (first author): Low-dose Diosbulbin-B (DB) activates tumor-intrinsic PD-L1/NLRP3 signaling pathway mediated pyroptotic cell death to increase cisplatin-sensitivity in gastric cancer (GC). PubMed 33579380
- Colloids Surf B Biointerfaces, 2021 (senior author): GPC3-targeted and curcumin-loaded phospholipid microbubbles for sono-photodynamic therapy in liver cancer cells. PubMed 33068823
- Biomed Pharmacother, 2019 (first author): Downregulation of CircRNA CDR1as specifically triggered low-dose Diosbulbin-B induced gastric cancer cell death by regulating miR-7-5p/REGγ axis. PubMed 31542615
- Int J Nanomedicine, 2019 (first author): An investigation on the cytotoxicity and caspase-mediated apoptotic effect of biologically synthesized gold nanoparticles using Cardiospermum halicacabum on AGS gastric carcinoma cells. PubMed 30787609
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion